TNFRSF17 and plasma cell myeloma: Combined with BCMA-specific CAR-T cells, lenalidomide promoted CAR-T-cell in vivo expansion (Figure 4), and significantly extended the survival of mice in a model of disseminated multiple myeloma [65].